State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen, 361102, China.
Eye Institute of Xiamen University, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Xiamen University, Xiamen, 361102, China.
Angew Chem Int Ed Engl. 2022 Dec 12;61(50):e202211674. doi: 10.1002/anie.202211674. Epub 2022 Nov 16.
A lack of targeting accuracy and radiosensitivity severely limits clinical radiotherapy. In this study, we developed a radiosensitizer comprised of Ru-based metal-organic nanostructures (ZrRuMn-MONs@mem) to optimize irradiation by maximizing reactive oxygen species (ROS) generation and CO release in X-ray-induced dynamic therapy (XDT). The well-designed nanostructures increase the direct absorption of radiation doses (primary radiation) and promote the deposition of photons and electrons (secondary radiation). The secondary electrons were trapped and transferred in the constrained MONs where they induce a cascade of reactions to increase the therapeutic efficiency. Meanwhile, the full-length antiglypican 3 (GPC3) antibody (hGC33) expressed a cell membrane coating enabling active targeting of tumor sites with optimized biocompatibility. The ZrRuMn-MONs@mem represents a starting point for advancing an all-around radiosensitizer that operates efficiently in clinical XDT.
缺乏靶向准确性和放射敏感性严重限制了临床放射治疗。在这项研究中,我们开发了一种由基于钌的金属有机纳米结构(ZrRuMn-MONs@mem)组成的放射增敏剂,通过最大限度地增加活性氧物种(ROS)的产生和 X 射线诱导的动态治疗(XDT)中的 CO 释放来优化照射。精心设计的纳米结构增加了对辐射剂量的直接吸收(初级辐射),并促进了光子和电子的沉积(次级辐射)。次级电子被捕获并转移到受限的 MONs 中,在那里它们引发级联反应以提高治疗效率。同时,全长 Glypican 3(GPC3)抗体(hGC33)表达细胞膜涂层,可实现与优化生物相容性的肿瘤部位的主动靶向。ZrRuMn-MONs@mem 为开发在临床 XDT 中高效运行的全方位放射增敏剂提供了起点。
Angew Chem Int Ed Engl. 2022-12-12
Photodiagnosis Photodyn Ther. 2019-10-10
ACS Appl Mater Interfaces. 2019-5-15
ACS Appl Mater Interfaces. 2017-9-5
Acc Chem Res. 2020-9-15
Antioxidants (Basel). 2025-6-15
Adv Sci (Weinh). 2024-8
Bioact Mater. 2024-3-14
Exploration (Beijing). 2023-7-27
Int J Nanomedicine. 2023